

Applicant : Yoshihito Ikeda et al.
Appln. No. : 10/018,770
Page : 2

In the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A drug composition comprising sucrose and a lecithin-modified superoxide ~~dismutase~~ dismutase represented by the following general formula (I):



wherein SOD' is a residue of superoxide dismutase; Q is a chemical crosslinking; B is a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; m is an average number of bonds of lysolecithin to one molecule of superoxide dismutase which is a positive number of 1 or more.

2. (Canceled).

3. (Canceled).

4. (Previously Presented) The drug composition according to claim 1 wherein a fatty acid content in the drug composition is 0.13-0.15 $\mu\text{mol}/\text{mg}$ protein.

5. (Canceled).

6. (Previously Presented) The drug composition according to claim 1 or 4 wherein Q is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{C}(\text{O})-$, n being an integer of 2 or more.

7. (Previously Presented) The drug composition according to claim 1 or 4 wherein SOD' is a residue of human superoxide dismutase.

Applicant : Yoshihito Ikeda et al.
Appln. No. : 10/018,770
Page : 3

8. (Previously Presented) The drug composition according to claim 1 or 4 wherein SOD' is a residue of a modified form of superoxide dismutase in which an amino acid in 111-position of an amino acid sequence of human superoxide dismutase is converted into S-(2-hydroxyethylthio) cysteine.

9. (Canceled).

10. (Previously Presented) The drug composition according to claim 1 or 4 wherein n is an integer of 2 to 10.

11. (Previously Presented) The drug composition according to claim 1 or 4 wherein m is a positive number of 1 to 12.

12. (Previously Presented) The drug composition according to claim 1 or 4 wherein the sucrose has been treated with activated charcoal.

13. (Previously Presented) The drug composition according to claim 1 or 4 wherein the drug composition is lyophilized.

14. (Previously Presented) The drug composition according to claim 1 or 4 wherein a weight ratio of the lecithin-modified superoxide dismutase to sucrose is 0.4/100-60/100.

15. (Canceled).

16. (Canceled).

17. (Canceled).

Applicant : Yoshihito Ikeda et al.
Appln. No. : 10/018,770
Page : 4

18. (Canceled).

19. (Currently Amended) A composition containing lecithin-modified superoxide dismutase that is rapidly-reconstituteable from a dry form and which has been stabilized against degradation due to cleavage within the lecithin moieties, comprising:

lyophilized lecithin-modified superoxide dismutase; and

sucrose in an amount that is effective to stabilize the lecithin-modified superoxide dismutase against degradation due to cleavage within the lecithin, whereby there is not any observable difference in the amount of degradation products before lyophilization and after re-dissolution, and wherein the composition completely dissolves in water in less than 10 seconds.